Rohan Dureja

Papers

Total Citations

H-Index

About

Rohan Dureja is a rising clinician-researcher whose work focuses on the intersection of thoracic oncology and immunotherapy, with a particular emphasis on optimizing treatment strategies for non-small cell lung cancer (NSCLC). His most cited study, "Outcomes of Resectable Locally Advanced Non-Small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy," draws on real-world, single-institution data to evaluate the efficacy of combining chemotherapy with immunotherapy before surgical resection. This work contributes critical evidence to the growing body of literature showing that neoadjuvant chemoimmunotherapy can significantly increase pathologic complete response rates in patients with locally advanced NSCLC—a finding that has the potential to reshape preoperative treatment protocols. Though early in his career, Dureja’s research addresses a pressing clinical need: translating promising clinical trial results into practical, patient-centered outcomes. His work underscores the transformative role of immunotherapy in lung cancer care and highlights the importance of institutional experiences in validating and refining new treatment paradigms. As his citation impact grows, Dureja is positioned to become a key voice in advancing multimodal approaches to resectable lung cancer.